Development Pipeline as at 30 June 2012
|
|
|
- Marshall Greene
- 6 years ago
- Views:
Transcription
1 Development Pipeline as at 30 June 2012 Line Extensions Axanum Brilinta/ Brilique EUCLID Brilinta/ Brilique PEGASUS- TIMI 54 Crestor # (dapagliflozin)/ FDC # proton pump + low dose aspirin FDC ADP ADP statin + FDC low dose aspirin associated peptic ulcer in high risk CV patients outcomes study in patients with PAD outcomes study in patients with ACS outcomes in subjects with elevated CRP III Withdrawn Launched 1H 2013* Approved III 3Q III 4Q III Launched Launched Launched diabetes III 3Q Q 2012 diabetes add on to DPP-4 diabetes add on to insulin and add-on to long-term data diabetes in patients with high CV risk - Study 18 and 19 long-term data III 1Q Q 2012 III 2Q Q 2012 III 1Q H 2013 diabetes triple therapy (dapa+met+ SU) III 1Q H 2013 Kombiglyze XR TM / Komboglyze TM FDC # ** DPP-4 + FDC diabetes III Launched Approved Approved Onglyza TM SAVOR-TIMI 54 # DPP-4 outcomes study III 2Q
2 Gastrointestinal Entocort Nexium FluMist/Fluenz Diprivan # EMLA # Oncology glucocorticoid steroid proton pump live, attenuated, intranasal virus vaccine sedative and anaesthetic local anaesthetic oestrogen Faslodex EGFR Iressa kinase long-acting β Oxis 2 steroid/ longacting β 2 Symbicort steroid/ longacting β 2 Symbicort steroid/ longacting β 2 Symbicort Crohn s disease / ulcerative colitis peptic ulcer bleeding III Launched Launched 2014 Launched III Filed*** Launched Launched III Launched Approved Launched conscious sedation topical anaesthesia 1 st line advanced breast cancer treatment beyond progression III Launched 2H 2013 Launched III Launched Launched Launched III III 1Q COPD III Launched Approved asthma / COPD * Nexium low-dose aspirin indications approved in 1H 2012 **Kombiglyze XR TM US; Komboglyze TM FDC EU ***2 nd CRL received in June 2011 III 4Q COPD III Launched Launched Filed Launched SMART III Launched Launched Launched
3 III/Registration ADP Brilinta/Brilique beta CAZ AVI # lactamase (CAZ104) / cephalosporin Q-LAIV Flu Vac*** Zinforo # (ceftaroline) naloxegol (NKTR-118) # Oncology Caprelsa Ranmark # (denosumab) live, attenuated, intranasal virus vaccine (quadrivalent) extended spectrum cephalosporin with affinity to penicillinbinding proteins oral peripherallyacting opioid VEGFR / EGFR kinase with RET kinase activity anti-rankl spleen fostamatinib # kinase (SYK) lesinurad selective of URAT1 arterial thrombosis III Launched Launched 1H 2013 Launched diabetes III 3Q 2007 Filed* Filed** 1H 2013 Filed serious infections seasonal pneumonia / skin infections opioid-induced constipation medullary thyroid cancer bone disorders stemming from bone metastasis rheumatoid arthritis chronic management of hyperuricaemia in patients with gout *CRL received in January 2012 **Positive opinion received from CHMP in 1H 2012 ***sbla in US, MAA in EU III 1Q 2012 N/A III Approved 4Q 2012 III 1Q 2007 N/A Filed** Filed III 2Q H H 2013 III Launched Launched 2014 Filed III N/A N/A Launched N/A III 3Q H H H 2013 III 4Q
4 s I and II AZD BHSD glaucoma II 1Q 2011 AZD2820 # melanocortin type 4 (MC4r) partial peptide obesity I 2Q 2011 Gastrointestinal tralokinumab AZD9773 # CXL # AZD5847 MEDI-550 MEDI-557 MEDI-559 AZD3241 AZD3480 # AZD5213 AZD6765 AZD1446 # anti-il-13 anti-tnfalpha polyclonal antibody beta lactamase / cephalosporin oxazolidinone antibacterial pandemic virus vaccine anti-rsv extended half-life paediatric RSV vaccine myeloperoxidase (MPO) alpha4/beta2 neuronal nicotinic histamine-3 NMDA alpha4/beta2 neuronal nicotinic ulcerative colitis II 2Q 2012 severe sepsis II 1Q 2008 MRSA II 4Q 2010 tuberculosis I 4Q 2009 pandemic prophylaxis RSV prevention in high-risk adults (COPD/CHF/ Other) RSV prophylaxis Parkinson s disease Alzheimer s disease Alzheimer s disease / ADHD major depressive disorder Alzheimer s disease I 2Q 2006 I 3Q 2007 I 4Q 2008 II 2Q 2012 II 3Q 2007 II 2Q 2012 II 3Q 2007 I 4Q 2008 MEDI-5117 anti-il-6 OA Pain I 2Q 2012
5 s I and II (continued) Oncology AZD4547 AZD8931 fostamatinib # FGFR kinase erbb kinase spleen kinase (SYK) anti-cd19 solid tumours II 4Q 2011 breast cancer chemo. combi./solid tumours haematological malignancies II 2Q 2010 II 1Q 2012 MEDI-551 # haematological II 1Q 2012 malignancies MEDI-573 # anti-igf solid tumours II 2Q 2012 MEDI-575 # anti-pdgfralpha glioblastoma NSCLC / II 4Q 2010 PARP gbrca olaparib II 1Q 2012 ovarian cancer selumetinib # (AZD6244) (ARRY ) MEK solid tumours II 4Q 2006 tremelimumab anti-ctla4 solid tumours II 3Q 2004 AZD1208 PIM kinase haematological malignancies I 1Q 2012 AZD1480 JAK1, 2 solid tumours I 2Q 2009 AZD2014 TOR kinase solid tumours I 1Q 2010 androgen AZD3514 prostate downregulator cancer I 3Q 2010 AZD5363 # AKT solid tumours I 4Q 2010 AZD8330 # (ARRY ) MEK solid tumours I 1Q 2007 MEDI-0639 MEDI-3617 # MEDI-565 # MEDI-6469 # moxetumomab pasudotox # selumetinib (AZD6244) (ARRY ) /MK2206 # anti-dll-4 anti-ang-2 anti-cea BiTE murine anti- OX40 anti-cd22 recombinant immunotoxin MEK/AKT solid tumours I 2Q 2012 solid tumours I 4Q 2010 solid tumours I 1Q 2011 solid tumours I 1Q 2006 haematological malignancies I 2Q 2007 solid tumours I 4Q 2009 volitinib # MET solid tumours I 1Q 2012
6 s I and II (continued) AZD2115 MABA COPD II 2Q 2012 AZD5069 CXCR2 asthma II 4Q 2010 AZD5423 AZD8683 benralizumab # brodalumab # mavrilimumab # MEDI-546 # MEDI-8968 # sifalimumab # tralokinumab SGRM muscarinic anti-il-5r anti-il-17r anti-gm- CSFR anti-ifnalphar anti-il-1r anti-ifnalpha anti-il-13 COPD II 4Q 2010 COPD II 4Q 2010 asthma / COPD II 4Q 2008 psoriasis / psoriatic arthritis / asthma rheumatoid arthritis II 4Q 2009 II 1Q 2010 SLE II 1Q 2012 COPD II 4Q 2011 SLE II 3Q 2008 asthma II 1Q 2008 AZD8848 TLR7 asthma I 2Q 2012 MEDI-2070 # anti-il-23 Crohn s disease I 2Q 2010 MEDI-4212 anti-ige asthma I 1Q 2012 MEDI-551 # MEDI-570 # MEDI-5872 # MEDI-7183 # MEDI-7814 MEDI-9929 # RDEA3170 anti-cd19 anti-icos anti-b7rp1 anti-a4b7 anti-c5/c5a anti-tslp selective of URAT1 scleroderma I 2Q 2010 SLE I 2Q 2010 SLE I 4Q 2008 Crohn s disease / ulcerative colitis I 3Q 2010 COPD I 1Q 2012 asthma I 4Q 2008 chronic management of hyperuricaemia in patients with gout I 3Q 2011
7 Development Pipeline - Discontinued Projects between 31 December 2011 and 30 June 2012 Area Under NCE AZD2927 Safety/Efficacy atrial fibrillation Area Under NCE AZD2423 Safety/Efficacy chronic neuropathic pain NCE AZD3839 Safety/Efficacy Alzheimer s disease NCE MEDI-578 Regulatory OA pain NCE TC-5214 Safety/Efficacy major depressive disorder (monotherapy) NCE TC-5214 Safety/Efficacy major depressive disorder (adjunct) Area Under NCE AZD5099 Safety/Efficacy serious infections NCE MEDI-534 Safety/Efficacy RSV/PIV prophylaxis Area Under NCE AZD1981 Safety/Efficacy asthma/copd NCE AZD2423 Safety/Efficacy COPD Comments As disclosure of compound information is balanced by the business need to maintain confidentiality, information in relation to some compounds listed here has not been disclosed at this time. Submission dates shown for assets in III and beyond.
Development Pipeline as at 31 December 2013
Line Extensions Cardiovascular Brilinta/ Brilique EUCLID Brilinta / Brilique PEGASUS-TIMI 54 Brilinta/ Brilique SOCRATES 1 Brilinta/ Brilique THEMIS Bydureon Dual Chamber Pen Bydureon EXSCEL Bydureon weekly
Partnering for Growth
Partnering for Growth JP Morgan Healthcare Conference Simon Lowth, Chief Financial Officer, AstraZeneca 9 January 2013 Partnering for Growth Agenda Our platforms for growth Partnering strategy and capabilities
Health Economics of Stratified Medicines An Industry Perspective
Health Economics of Stratified Medicines An Industry Perspective Gavin Lewis, Global Head of Oncology Market Access, AstraZeneca Health Economics of Stratified Medicine, London 5 th October 2016 Health
Creating an environment where science thrives
Creating an environment where science thrives Dr Menelas Pangalos EVP Innovative Medicines & Early Development 2 July 2014 What we will cover today AstraZeneca today: science at the heart of everything
EU5. prevalence 29.4m. diagnosed 20.4m. treated 18.6m. GINA 1 4.0m. GINA 2 2.2m. GINA 3 3.5m. GINA 4 8.3m. GINA 5 0.6m
Epidemiology This Epidemiology appendix contains estimates of patient data for a number of diseases and potential indications relevant for select AstraZeneca in-market products and pipeline projects. All
H1 Results 30 July 2015
H1 Results 30 July 2015 Forward-looking statements In order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities Litigation Reform Act 1995, we are providing the following
A focused biopharmaceutical company. General presentation for investors and analysts 20 June 2018
A focused biopharmaceutical company General presentation for investors and analysts 20 June 2018 Forward-looking statements In order, among other things, to utilise the 'safe harbour' provisions of the
Clinical Trials Appendix. Q Results Update
Clinical Trials Appendix Q4 2014 Results Update The following information about ongoing AstraZeneca clinical studies in s I-IV has been created with selected information from clinicaltrials.gov to facilitate
What science can do. AstraZeneca 2014 In Brief
What science can do AstraZeneca 2014 In Brief At AstraZeneca, each and every one of us is bold in the belief that science should be at the centre of everything we do. Science compels us to push the boundaries
AstraZeneca LCM development programmes Q1 2014
AstraZeneca LCM development programmes Q1 2014 BRILINTA/BRILIQUE (ADP receptor antagonist) PARTHENON development programme s with prior MI PEGASUS NCT01225562 N= 21000 ARM 1: Ticagrelor 90 mg BD ARM 2:
Q Results. 29 April 2016
Q1 2016 Results 29 April 2016 Forward-looking statements In order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities Litigation Reform Act 1995, we are providing
2Q and Half Year Results 2010
2Q and Half Year Results 2010 Cautionary statement regarding forward-looking statements In order, among other things, to utilise the safe harbour provisions of the US Private Securities Litigation Reform
Pfizer Pipeline. May 10, 2012
Pfizer Pipeline May 10, 2012 Disclaimer As some programs are still confidential, some candidates may not be identified in this list. In these materials, Pfizer discloses Mechanism of Action (MOA) information
Pfizer Pipeline. August 9, 2012
Pfizer Pipeline August 9, 2012 Disclaimer As some programs are still confidential, some candidates may not be identified in this list. In these materials, Pfizer discloses Mechanism of Action (MOA) information
GSK Oncology R&D Update
GSK Oncology R&D Update Axel Hoos, MD Senior Vice President, Oncology R&D February 2019 Cautionary statement regarding forward-looking statements This presentation may contain forward-looking statements.
Pfizer Pipeline. February 28, 2012
Pfizer Pipeline February 28, 2012 Disclaimer As some programs are still confidential, some candidates may not be identified in this list. In these materials, Pfizer discloses Mechanism of Action (MOA)
Building Collaborative Healthcare Ecosystems for BETTER PATIENT OUTCOMES
Building Collaborative Healthcare Ecosystems for BETTER PATIENT OUTCOMES Pei-Chieh Fong, Pharm.D. Medical Director, AstraZeneca 19 November 2018 2 https://vimeopro.com/silverfish/healthcare/video/151376998
A focused biopharmaceutical company. General presentation for investors and analysts January 2019
A focused biopharmaceutical company General presentation for investors and analysts January 2019 Forward-looking statements In order, among other things, to utilise the 'safe harbour' provisions of the
H Results. Media presentation, conference call and webcast 26 July 2018
H1 2018 Results Media presentation, conference call and webcast 26 July 2018 Forward-looking statements In order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities
New Avenues for the development and evaluation of therapy: Complex, multi-pronged, not one size fitting all
New Avenues for the development and evaluation of therapy: Complex, multi-pronged, not one size fitting all Antoine Yver MD MSC Senior VP & Head Oncology Global Medicines Development AstraZeneca, Gaithersburg
How much do you know about illnesses or health problems for your parents, grandparents, brothers, sisters, and/or children? 1 A lot Some None at all
Family Health History Please answer each question as honestly as possible. There are no right or wrong answers to nay of the questions. It is important that you answer as many questions as you can. We
Pfizer Pipeline. As of May 12, 2011
Pfizer Pipeline As of May 12, 2011 Disclaimer As some programs are still confidential, some candidates may not be identified in this list. In these materials, Pfizer discloses Mechanism of Action (MOA)
Oncology Drug Development
Oncology Drug Development Advantages and challenges of using stratified clinical studies Simon J Hollingsworth The 18th Anti-Tumour Drug Development Forum 21 February Japan Stratified Medicine In The Clinic
Kentucky Department for Medicaid Services Pharmacy and Therapeutics Advisory Committee Recommendations
Kentucky Department for Medicaid Services Pharmacy and March 15, 2018 The following chart provides a summary of the recommendations that were made by the Pharmacy and Therapeutics (P&T) Advisory Committee
Clinical Trials Appendix Q Update
Clinical Trials Appendix Q3 2015 Update The following information about AstraZeneca clinical studies in Phases I-IV has been created with selected information from clinicaltrials.gov to facilitate understanding
Bank of America Merrill Lynch 2016 Health Care Conference
Bank of America Merrill Lynch 2016 Health Care Conference Dr. Steven Stein Chief Medical Officer David Gryska Chief Financial Officer May 11, 2016 Forward Looking Statements Except for the historical information
HEALTH MATTERS, INC. SUMMARY OF PROJECTS AND KEY ACCOMPLISHMENTS TO 2016
Selected 2016 Highlights Epidemiologic research on chronic kidney disease and fistula patency, solid and hematologic malignancies Health economics and outcomes research on beta3-agonist treatment for overactive
Jefferies Healthcare Conference. June 6, 2018
Jefferies Healthcare Conference June 6, 2018 Forward-Looking Statements and Non-GAAP Financial Information Some statements in this presentation may be forward-looking statements for purposes of the Private
Summary of Strategic Competitive Analysis and Publication Planning
Summary of Strategic Competitive Analysis and Publication Planning Carole Alison Chrvala, PhD 919.545.2149 (Work) 919.951.5230 (Mobile) cchrvala@centurylink.net www.healthmattersmedwriting.com 1 Briefing
Q Results. Conference call and webcast for investors and analysts, London, UK 27 April 2017
Q1 2017 Results Conference call and webcast for investors and analysts, London, UK 27 April 2017 Forward-looking statements In order, among other things, to utilise the 'safe harbour' provisions of the
Pfizer Pipeline. November 8, 2012
Pfizer Pipeline November 8, 2012 Disclaimer As some programs are still confidential, some candidates may not be identified in this list. In these materials, Pfizer discloses Mechanism of Action (MOA) information
US Postmarketing Study Commitments (Updated June 2016) Compound Name
Compound US Postmarketing Study s (Updated June 2016) Compound Arimidex Description of NDA Number Date Given Description of NDA Number Although not required to obtain pediatric exclusivity, we request
Pharmacotherapy Handbook
Pharmacotherapy Handbook Eighth Edition Barbara G. Wells, PharmD, HP, FCCP, BCPP Dean and Professor Executive Director, Research Institute of Pharmaceutical Sciences School of Pharmacy, The University
Delivering in Respiratory ATS Analyst Briefing
Delivering in Respiratory ATS Analyst Briefing James Ward-Lilley, VP of RIA Therapy Area AstraZeneca Bing Yao, SVP & Head RIA imed MedImmune 20 May 2014 San Diego Cautionary statement regarding forward-looking
SCHNEIDER MEDICAL GROUP, PA History Intake Form (Please Print)
History Intake Form Patient Name: Date of Visit: Briefly State the reason for the visit: Date of Birth: Physician Use Only - History and Present: 1. 2. 3. 4. 5. Page 1 of 10 Review of Symptoms HEAD NO
STOPP START Toolkit Supporting Medication Review in the Older Person
STOPP START Toolkit Supporting Medication Review in the Older Person STOPP: Screening Tool of Older People s potentially inappropriate Prescriptions START: Screening Tool to Alert doctors to Right (appropriate,
Taking our science to the ASCO 2018 Annual Meeting. Investor and analyst planner and information pack Chicago, Illinois, USA 01 June 2018
Taking our science to the ASCO 2018 Annual Meeting Investor and analyst planner and information pack Chicago, Illinois, USA 01 June 2018 Forward-looking statements In order, among other things, to utilise
LECOM Health Ophthalmology
Patient Name: Date of Birth: New Patient Questionnaire Your answers will be used by your healthcare provider get an accurate history of your medical conditions and ocular concerns. If you are uncomfortable
New Product to Market: Trelegy Ellipta Magellan Health, Inc. All rights reserved.
Drug Review and The following tables list the Agenda items as well as the that are scheduled to be presented and reviewed at the March 15, 2018 meeting of the Pharmacy and Therapeutics Advisory Committee.
Jefferies 2017 Global Healthcare Conference. Stephen Doberstein, Ph.D. Senior Vice President & Chief Scientific Officer
Jefferies 2017 Global Healthcare Conference Stephen Doberstein, Ph.D. Senior Vice President & Chief Scientific Officer June 7, 2017 This presentation includes forward-looking statements regarding Nektar
33 rd Annual J.P. Morgan Healthcare Conference. January 2015
33 rd Annual J.P. Morgan Healthcare Conference January 2015 Forward-looking Statements This presentation contains forward-looking statements, which express the current beliefs and expectations of management.
H Results. Presentation, conference call and webcast for investors and analysts 26 July 2018
H1 2018 Results Presentation, conference call and webcast for investors and analysts 26 July 2018 Forward-looking statements In order, among other things, to utilise the 'safe harbour' provisions of the
Barbara G. Wells, PharmD, FASHP, FCCP, BCPP Dean and Professor School of Pharmacy, The University of Mississippi Oxford, Mississippi
Barbara G. Wells, PharmD, FASHP, FCCP, BCPP Dean and Professor School of Pharmacy, The University of Mississippi Oxford, Mississippi Joseph T. DiPiro, PharmD, FCCP Panoz Professor of Pharmacy, College
Patient Information. Patient Name: DOB: Last First M.I. Home Address: City: State: Zip: Home Phn: Cell Phn: Alt. Phn: SSN:
Dr. Alvin Huang, M.D., F.A.C.E. 1650 W. Rosedale St. Suite 301, Fort Worth TX 76104 (P) 817-259-4333 (F) 817-820-0303 Patient Information Patient Name: DOB: Last First M.I. Home Address: City:_ State:
SUPPLEMENTARY INFORMATION
Supplementary Information S3 TAM- family small molecule kinase inhibitors in development Compound Indication(s) Target Profile Develop Primary Target MERTK TYRO3 Other targets ment Phase Refs Cabozantinib
A pipeline-driven transformation. SEB Nordic Seminar January 2018
A pipeline-driven transformation SEB Nordic Seminar 2018 09 January 2018 Forward-looking statements In order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities Litigation
Clinical Pharmacology and Drug Therapy
Oxford Textbook of Clinical Pharmacology and Drug Therapy THIRD EDITION D. G. Grahame-Smith CBE, MBBS, PhD, FRCP Emeritus Professor of Clinical Pharmacology, University of Oxford and J.K. Aronson MBChB,
JP Morgan Healthcare Conference. Howard Robin President & CEO January 9, 2018
JP Morgan Healthcare Conference Howard Robin President & CEO January 9, 2018 This presentation includes forward-looking statements regarding Nektar s proprietary drug candidates, the timing of the start
Incyte Corporation. Hervé Hoppenot President & CEO. 34th J.P. Morgan Annual Healthcare Conference January 11, 2016
Incyte Corporation Hervé Hoppenot President & CEO 34th J.P. Morgan Annual Healthcare Conference January 11, 2016 Forward-looking Statements Except for the historical information set forth herein, the matters
In your own words, please write the reason you are here. Please be specific, putting in dates as necessary. Use the back of the form if needed.
Name: SS# In your own words, please write the reason you are here. Please be specific, putting in dates as necessary. Use the back of the form if needed. Patient Medical, Surgical and Family History Review
Jefferies 2016 Healthcare Conference. Reid Huber, PhD Chief Scientific Officer
Jefferies 2016 Healthcare Conference Reid Huber, PhD Chief Scientific Officer June 8, 2016 Forward-looking Statements Except for the historical information set forth herein, the matters set forth in this
Q Results. Conference call and webcast for investors and analysts 18 May 2018
Q1 2018 Results Conference call and webcast for investors and analysts 18 May 2018 Forward-looking statements In order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities
Reported Earnings Per Share (EPS) $0.88 (34) (34) $0.34 (37) (36) Core EPS $1.88 (37) (37) $0.71 (37) (33)
AstraZeneca PLC 8 November 2018 07:00 GMT Year-to-Date and Q3 2018 Results AstraZeneca Returns to Sales Growth; New Medicines and Emerging Markets Lead the Way Product Sales increased by 4% in the year
FDA Approval LIST. WellINFORMED. Generic Name(s) Brand Name (manufacturer) Therapeutic Use. Brief Description. Potential Impact.
FDA Approval LIST Formulary management is one way to bring down drug costs, and deciding which medications to include on a formulary is part of this process. New drug releases are generally associated
Selumetinib (AZD6244; ARRY ) Pediatric MATCH. George Kirk June 2016
Selumetinib (AZD6244; ARRY-142886) Pediatric MATCH George Kirk June 2016 MEK activation and selumetinib MOA MEK is a fundamental component of the MAPK pathway a central oncogenic signalling pathway frequently
3. Has the patient shown improvement in signs and symptoms of the disease? Y N
Pharmacy Prior Authorization MERC CARE (MEDICAID) Renflexis (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign and date. Fax
Patient Name Date of Birth MALE / FEMALE Date. Left handed or Right handed. Marital Status: Single Married Divorced Widowed Children?
PH NEW PATIENT HISTORY Patient Name Date of Birth MALE / FEMALE Date Occupation: Left handed or Right handed Marital Status: Single Married Divorced Widowed Children? Y or N # Previous Treating Physician:
Patient Interview Form
Page 1 of 5 Patient Interview Form Patient Information First Name: Date Of Birth: Last Name: Age: Email Please check one as your preferred email for communications Personal: Work: Race Select one or more
PATIENT INFORMATION. Last Name First Name MI. Address. City State Zip. Cell Phone _( ) Home Phone _( ) May we contact you by ?
PATIENT INFORMATION date: Last Name First Name MI Address City State Zip Cell Phone _( ) Home Phone _( ) Email May we contact you by email? Yes No Date of Birth Age Marital Status Patient s Occupation
Cardiovascular & Metabolism James List, M.D., Ph.D. Global Therapeutic Area Head, Cardiovascular & Metabolism
Cardiovascular & Metabolism James List, M.D., Ph.D. Global Therapeutic Area Head, Cardiovascular & Metabolism Cardiovascular & Metabolism 1 Our Vision for the Future To improve the lives of the millions
Immuno-Oncology. Axel Hoos, MD, PhD Senior Vice President, Oncology R&D. February 24, 2016
Immuno-Oncology Axel Hoos, MD, PhD Senior Vice President, Oncology R&D February 24, 216 GSK Pipeline Oncology R&D strategy Focusing on 3 areas fundamental to oncology Cancer Epigenetics Long-Term Survival
Clinical trials appendix Q update
Clinical trials appendix Q1 2016 update The following information about AstraZeneca clinical trials in Phases I-IV has been created with selected information from clinicaltrials.gov to facilitate understanding
R&D Pipeline (May 2006)
R&D Pipeline (May 2006) 1Japan (1)Approved Product Name (Code No) Vesicare (YM905) Funguard (FK463) (Approval Date ) solifenacin (April 2006) micafungin (April 2006) Urinary frequency, urinary incontinence
Major R&D Pipeline As of January 2016
Major R&D Pipeline As of January 2016 Therapeutic area Cardiovascular- Metabolics Phase 1 Phase 2 Phase 3 Application DS-1040 (Acute ischemic stroke / TAFIa DS-2330 (Hyperphosphatemia) DS-9231/TS23 (Thrombosis
Delivering Scientific Advances That Impact Patients Lives
Delivering Scientific Advances That Impact Patients Lives Geno Germano President / General Manager Specialty Care & Oncology Business Units J.P. Morgan Healthcare Conference January 11, 2011 Forward-Looking
R&D Pipeline (November 2005)
R&D Pipeline (November 2005) 1Japan (1)Filed Code No YM905 YM177 YM152 FK463 Generic Name (Filing Date ) solifenacin (Aug 2004) celecoxib (Dec 2002) finasteride (Dec1994) micafungin (July 2004) (Oct 2005)
Development Pipeline Progress Status. February 1, 2019
Development Pipeline Progress Status February 1, 2019 /9 Development status of OPDIVO (nivolumab) (1) Target disease JAPAN US/EU KR/TW Melanoma (1 st ) Approved Approved Approved Melanoma (Adjuvant Therapy)
Our efforts bound for the No.1 company in Japan
Japan pharmaceuticals companies conference by Deutsche Securities Inc Our efforts bound for the No.1 company in Japan Thursday, September 22, 2011 Joji Nakayama, President and CEO Major Topics for FY2011
Department of Pharmacology VMMC and Safdarjung Hospital
4 th Semester Teaching Schedule, January, 2017, Batch-2015 03/01/2017, 03/01/2017, 10/01/2017, 10/01/2017, 10/01/2017, 17/01/2017, 17/01/2017, 17/01/2017, 24/01/2017, 24/01/2017, 24/01/2017, 31/01/2017,
Texas Vendor Drug Program. Formulary Drug Index File Layout. Layout effective: Jul. 2, 2018 Document update: Oct. 1, 2018
Texas Vendor Drug Program Formulary Drug Index File Layout Layout effective: Jul. 2, 2018 Document update: Oct. 1, 2018 The Vendor Drug Program provides a weekly update of resource data available for download
DONE! You can now close the browser.
Visit My Doctor Online at kp.org/mydoctor. Prepare for your visit This form will help you prepare for your upcoming visit with your doctor. You can complete it on your computer (Mac or PC) and e-mail it
Patient Interview Form
Patient Interview Form Patient Information First Name: MRN: Age: Last Name: Date Of Birth: tes: Contact Preference Email Telephone call/leave message Patient declines to specify Email Please check one
Liver Health: Do you have liver problems? Yes No If so, please specify:
Medical History General Last Name: First Name: Date of Birth: Age: Contact Number: Are you in good health to the best of your knowledge Medical Information: Please list any physicians you see and their
New Merck Pipeline. Combined Legacy Merck and Schering-Plough Research Pipelines
New Merck Pipeline Combined Legacy Merck and Schering-Plough Research Pipelines November 4, 2009 Forward-Looking Statement This presentation contains "forward-looking statements" as that term is defined
Pharmacology. An Introduction. Henry Hitner, Ph.D. Barbara Nagle, Ph.D. Learn. Neuroscience, Physiology,
Pharmacology An Introduction Henry Hitner, Ph.D. Department Neuroscience, Physiology, Philadelphia College of Osteopathie Medicine Philadelphia, Pennsylvania Adjunct Professor, Pharmacology Physician Assistant
CHRONIC MEDICINE PROGRAMME GENERAL INFORMATION LETTER
RAND WATER MEDICAL SCHEME RAND WATER MEDICAL SCHEME CHRONIC MEDICINE PROGRAMME GENERAL INFORMATION LETTER LIST OF CHRONIC CONDITIONS Conditions covered under s chronic medication benefit are detailed below.
CHRONIC TREATMENT GUIDELINES
CHRONIC TREATMENT GUIDELINES REGISTRATION OF CHRONIC CONDITIONS You can only access benefits for chronic medication, as listed below, if your prescribing/treating doctor or pharmacist registers your chronic
ASTRAZENECA. Moderator: Pascal Soriot July 30, :00 BST
Page 1 ASTRAZENECA July 30, 2015 12:00 BST Operator: This is conference # 75191806. Good afternoon. Welcome, ladies and gentlemen, to AstraZeneca s First Half Year Results Analyst Conference. Before I
AstraZeneca Oncology. Cautionary statement regarding forward-looking statements. Mondher Mahjoubi Head, Oncology Global Portfolio & Product Strategy
AstraZeneca Oncology Mondher Mahjoubi Head, Oncology Global Portfolio & Product Strategy Sunday 28 September, 2014 Madrid, Spain 140313 G5 Update vdraft 1 Cautionary statement regarding forward-looking
CENTRAL COAST ORTHOPEDIC MEDICAL GROUP Medical History Questionnaire GENERAL INFORMATION
GENERAL INFORMATION Last Name: First Name: What name do you prefer to be called? Age: DOB: / / Height: Weight: Left or Right Handed : Right Left Marital Status: M S D W Name of spouse or significant other:
Presentation to 2019 JP Morgan Healthcare Conference
For immediate release 10 January 2019 Presentation to 2019 JP Morgan Healthcare Conference Please find attached CSL Limited s presentation at the 2019 JP Morgan Healthcare Conference. For further information,
proposed set to a required subset of 3 to 5 measures based on the availability of electronic
CMS-0033-P 143 proposed set to a required subset of 3 to 5 measures based on the availability of electronic measure specifications and comments received. We propose to require for 2011 and 2012 that EP's
STOPP and START criteria October 2011
# START and STOPP are newer criteria to identify potentially inappropriate medications in elderly, including drug drug and drug disease interactions, drugs which increase risk of falls and drugs which
2. Does the patient have a diagnosis of ulcerative colitis or Crohn s? Y N
Pharmacy Prior Authorization AETA BETTER HEALTH LOUISIAA (MEDICAID) Remicade (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign
Development status of OPDIVO (nivolumab) 1
November 2, 2018 Development status of OPDIVO (nivolumab) 1 Target disease JAPAN US/EU KR/TW Melanoma (1 st ) Approved Approved Approved Melanoma (Adjuvant Therapy) Approved Approved(EU) Non-small cell
Past Medical History. Chief Complaint: Patient Name: Appointment Date: Page 1
Appointment Date: Page 1 Chief Complaint: (Please write reason, symptoms, condition or diagnosis that prompts your appointment) Past Medical History PERSONAL SKIN HISTORY YES NO Yes - Details Melanoma
Enhancing Corporate Value
Goldman Sachs Twenty Sixth Annual Healthcare Conference Enhancing Corporate Value Eisai Co., Ltd. June 15, 2005 Please refer to the US Roadshow, June 2005 material in our WEB site for further information
Mrs. Isabelle GAUDIN 22 years experience in Clinical Research LEAD CRA / SENIOR CLINICAL RESEARCH ASSOCIATE
Sté Aid ARC 36, Comba dels Martirs 11570 PALAJA FRANCE Fax : +33 4 68 47 03 52 Mob : +33 6 14 68 71 71 E-mail : isabelle.gaudin@aidarc.com Mrs. Isabelle GAUDIN 22 years experience in Clinical Research
Forward-looking statements
Investor Roadshow Forward-looking statements In order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities Litigation Reform Act 1995, we are providing the following
SECTION I: ACTIVE DIAGNOSES. Active Diagnoses in the Last 7 Days
SECTION I: ACTIVE DIAGNOSES Intent: The items in this section are intended to code diseases that have a relationship to the resident s current functional status, cognitive status, mood or behavior status,
2018 MIPS Reporting Family Medicine
2018 MIPS Reporting Family Medicine Quality Reporting Requirements: Report on 6 quality measures or a specialty measure set Include at least ONE outcome or high-priority measure Report on patients of All-Payers
Health economics for stratified medicine. Friday 16 September 2016, Academy of Medical Sciences
Health economics for stratified medicine Friday 16 September 2016, Academy of Medical Sciences Key issues in the health economics of stratified medicine Adrian Towse Director of the Office of Health Economics
11/5/2011. Disclosures. Key References. JAK Inhibitors. Tofacitinib(CP ): Phase 2 Studies
Disclosures KINASE INHIBITORS IN RA Michael E. Weinblatt, M.D. Dr. Weinblatt has been a consultant to the following companies involved in the JAK and SYK pathways in RA Pfizer Vertex Astellas Rigel Astra-Zeneca
LYNPARZA RECEIVES ADDITIONAL AND BROAD APPROVAL IN THE US FOR OVARIAN CANCER
This announcement contains inside information 18 August 2017 07:00 BST LYNPARZA RECEIVES ADDITIONAL AND BROAD APPROVAL IN THE US FOR OVARIAN CANCER Lynparza's new tablet formulation approved as maintenance
Index. Note: Page numbers of article titles are in boldface type.
Note: Page numbers of article titles are in boldface type. A Adaptive immune response biologic response modifiers and, 735 737 S-Adenosylmethionine (SAMe) for hepatitis, 825 826 Albinterferon for hepatitis,
Late-stage Pipeline Review
Late-stage Pipeline Review 9 January 2013 Dr Patrick Vallance President, Pharmaceutical R&D 1 Strategy to maximise growth and returns to shareholders Re-engineered drug discovery organisation Grow a diversified
Full-Year and Q Results. Live presentation, conference call and webcast for investors and analysts 2 February 2018
Full-Year and Q4 2017 Results Live presentation, conference call and webcast for investors and analysts 2 February 2018 Forward-looking statements In order, among other things, to utilise the 'safe harbour'
ASCO 2018 investor event: a leading, diversified oncology business
ASCO 2018 investor event: a leading, diversified oncology business Hyatt Conference Columbus2018 Chicago, Illinois, USA 04 June 2018 Forward-looking statements In order, among other things, to utilise